Cantor Fitzgerald Maintains Neutral on ADMA Biologics, Raises Price Target to $13
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Neutral and raises the price target from $12 to $13.
Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Neutral and raises the price target from $12 to $13.